Boston Scientific ta tashi da kashi 20%, Medtronic ta tashi da kashi 8%, Fuji Health ta fadi da kashi 2.9%, yayin da Olympus China ta fadi da kashi 23.9%.
Na yi ƙoƙarin yin nazarin ayyukan tallace-tallace na kamfanoni da dama a manyan yankuna na duniya ta hanyar rahotannin kuɗinsu don fahimtar kasuwar likitanci (ko endoscopy) da kuma yadda nau'ikan samfura daban-daban ke bayyana samfuransu da ayyukansu a China. Manufar ita ce gano canje-canjen da ke shafar kudaden shiga.
Nemo Abubuwan Da Suka Shafi Kayayyaki: Kwatanta canjin kudaden shiga a yankuna daban-daban na kamfanoni daban-daban na ƙasashen duniya bai nuna wani tsari bayyananne ba. Idan akwai wani tsari, to tallace-tallace sun fi kyau a ƙasashensu, tare da raguwa mai yawa a China idan aka kwatanta da wannan lokacin a bara. Kasuwannin da ke tasowa a Asiya (ban da China) sun yi fice a Turai. Tasirin China kan kamfanoni na ƙasashen duniya ya bayyana a fili a cikin kayan aiki da kayan amfani masu daraja, tare da kayan aiki suna nuna babban tasiri. A mahangar kamfanoni na ƙasashen duniya waɗanda suka ƙware a cikin kayan amfani masu daraja na zamani, Amurka ita ce kasuwa mafi girma, sai Turai da Japan. An ambaci China a matsayin kasuwa mai tasowa galibi saboda VBP (Kayayyakin Magunguna na Vacuum). Wani abu da ya zama ruwan dare shine babban mai da hankali kan ci gaban kwayoyin halitta (sabbin samfura, kirkire-kirkire, haɓaka masu amfani) tsakanin kamfanoni na ƙasashen duniya. Sun jaddada kirkire-kirkire da dabarun samfura daban-daban a yankuna bisa ga matakai daban-daban na ci gaban likita. Medtronic da Olympus sun kuma ambaci robotics, suna nuna tasirinsa ga kasuwancin da ke akwai. Kamfanonin biyu suna da kasuwancin da ke da alaƙa da AI.
Idan kuna sha'awa, da fatan za a ci gaba da karatu don cikakken bayani.
Idan aka duba Fuji, kasuwa ta yi kama da babu komai a ciki, amma komai a wajen Japan yana raguwa, inda Turai ke fuskantar raguwa mafi sauri. Idan aka duba Obama, da alama a duk duniya, ban da Asiya da Oceania (ban da Japan da China), komai yana fuskantar raguwa mai yawa, musamman China da Arewacin Amurka. Idan aka duba Boston Scientific da Medtronic, yanayin duniya yana da kyau sosai.
Kudaden shiga na Fujifilm na kwata na farko na 2025 (Afrilu-Yuni), gami da kyamarorin kasuwanci, sun karu da kashi 0.1% gaba ɗaya, tare da kashi 7.4% a Japan, -0.1% a Amurka, -6.9% a Turai, da kuma -3.6% a Asiya da sauran yankuna.
A fannin kiwon lafiya, ba a bayar da wani bayani game da tallace-tallace ta hanyar yankin kasuwanci ba; alkaluman da ke cikin rukuni ne kawai ake da su. Kudaden shiga na kiwon lafiya sun kai ¥ biliyan 228.5, raguwar kashi 2.9% a shekara-shekara. Tallace-tallacen kayan aikin likita (fim) a China sun ragu (mai yiwuwa saboda ƙarancin buƙata?), kuma kayan aikin gano X-ray suma sun ragu (mai yiwuwa saboda ƙarancin oda mai yawa a wannan kwata idan aka kwatanta da bara, lokacin da aka sami ƙarin oda mai yawa). Dangane da endoscopes, jerin ELUXEO 8000 sun sami gagarumar tallace-tallace a Turai a watan Mayu na 2025; duk da haka, kasuwar endoscope gaba ɗaya ta kasance ƙasa idan aka kwatanta da bara, kodayake an sami manyan oda a Turkiyya da Tsakiya da Kudancin Amurka.
Ci gaban Olympus na Afrilu-Yuni 2025 ya kasance -12.1% (Japan -8.9%, Arewacin Amurka -18.9%, Turai -7.5%, China -23.9%, Asiya (ban da China da Japan) da Oceania 7.62%, sauran yankuna 17.8%). An danganta raguwar da aka samu a Turai da raguwar na'urorin tiyata na endoscopes, wanda aka bayyana ta hanyar adadi mai yawa na umarnin da aka bayar a Turai a daidai wannan lokacin a bara, irin wannan bayanin da Fujifilm ta bayar. Tsarin VISERA ELITE III ci gaba ne mai kyau a tiyatar Turai, amma ba a yin aikin gastroscopy da colonoscopy akai-akai a ɗakin tiyata. Don magance raguwar riba, ana aiwatar da rage farashi ta hanyar rage farashin da ba na asali ba da kuma inganta tsarin kashe kuɗi. Faɗaɗa sawun fasahar likitanci da kuma haɓaka ci gaba a fannin na'urorin robotics na endoscopic yana nufin cimma ci gaban kudaden shiga a nan gaba a wannan fanni. Olympus tana ƙarfafa haɗin gwiwa da saka hannun jari na waje ta hanyar haɗin gwiwa: A ranar 25 ga Yuli, 2025, Ƙungiyar, ta hanyar haɗin gwiwar reshenta na Olympus Corporation of the Americas, ta shiga yarjejeniyar saka hannun jari tare da Revival Healthcare Capital LLC don haɗin gwiwa kafa kamfanin haɗin gwiwa Swan EndoSurgical, Inc., wanda ke mai da hankali kan bincike da haɓaka samfuran robotic endoscopic.
Boston Scientific: Daga watan Yuli zuwa Satumba na 2025, kudaden shiga sun karu da kashi 20.3% a kowace shekara, inda bangaren likitanci da tiyata ya karu da kashi 16.4% (urology 28.1%, endoscopy 10.1%, neurology 9.1%), organic ci gaban 7.6%, kuma cardiovascular partnerships ya karu da kashi 22.4%, organic ci gaban 19.4%. Babu wani bayani da aka bayar game da China, sai dai an ambaci cewa VBP (tsakanin sayayya) a China ya haifar da raguwar kudaden shiga na gefe, wanda ya haifar da raguwar lambobi daya kawai. Kasuwancin intraluminal endoscopic ya nuna AXIOS™ (stent) da OverStitch™ (suture), yana nuna gagarumin ribar kudaden shiga na Boston Scientific daga sabbin kayayyaki.
Kudaden shigar Amurka sun karu da kashi 27%, wanda ya kai sama da kashi 65% na kudaden shigar duniya.
Turai, Gabas ta Tsakiya, da Afirka (EMEA): Tallace-tallace sun karu da kashi 2.6%.
Turai: Babban dalilin shine shawarar da kamfanin ya yanke a kwata na biyu na 2025 na dakatar da tallace-tallace na tsarin bawul ɗin aortic na ACURATE neo2™ da ACURATE Prime™ a duniya, wanda ya samar da kimanin dala miliyan 50 a tallace-tallace na kwata na duniya a daidai wannan lokacin a bara. Da ba a dakatar da tallace-tallace ba, da karuwar kwata na uku ta kai kashi 9% bisa ga wannan adadi. Bukatar ayyukan endoscopic intracavitary (AXIOS™, OverStitch™) da zurfin motsa kwakwalwa (DBS) sun kasance daidai.
Asiya Pacific (APAC): Ci gaban kashi 17.1%, wanda galibi Japan, kasuwa ce mai girma ke jagoranta.
Latin Amurka da Kanada (LACA): Ci gaban kashi 10.4%.
Kasuwannin da ke Tasowa: Ci gaban kashi 11.8%.
Ci gaban Medtronic a kwata na 1 na shekarar 2025 ya kasance da kashi 8.4% gaba ɗaya, inda kasuwancin zuciya da jijiyoyin jini suka karu da kashi 9.3%, ilimin jijiyoyi 4.3%, da kuma tiyata 4.4%. (Surgical & Endoscopy sun ga ci gaban kwayoyin halitta na kashi 2.3%, tare da fasahar rufe jijiyoyin LigaSure™ da ke riƙe da hannun jarin kasuwa a kwata na 12 a jere, wanda ya cimma babban ci gaban duniya mai lamba ɗaya; duk da haka, ci gaban ya takaita ne sakamakon matsin lamba na ɗan gajeren lokaci daga buƙatar tiyatar bariatric a kasuwar Amurka da kuma maye gurbin tiyatar gargajiya ta hanyar tiyatar robot. An tsara ƙaddamar da robot ɗin Hugo™ da Amurka ta yi (a rabin na biyu na shekara) zai zama babban abin da zai haifar da ci gaban wannan ɓangaren a nan gaba.) Kasuwancin ciwon suga ya karu da kashi 11.5%.
Ta yanki: Dalar Amurka biliyan 4.24, karuwar kashi 3.5%, wanda ya kai kashi 49% na kasuwar duniya. Kasuwannin duniya sun karu da kashi 13.6%, inda cututtukan zuciya da jijiyoyin jini suka karu da kashi 12.6%, ilimin jijiyoyi 5.4%, tiyatar likita 7.5%, da kuma ciwon suga 16.7%. Ci gaban kasuwar duniya ya samo asali ne daga kasuwar Japan (cirewar zuciya, TAVR), kasuwar Turai (neuromodulation, tiyatar robotic), da kasuwannin da ke tasowa (kayan aikin tiyata na asali, na'urorin auna sukari). Kasuwar Amurka ta mayar da hankali kan inganta kayayyakin kirkire-kirkire masu daraja (kamar PFA, RDN). (Shirye-shirye), kasuwar duniya ta mayar da hankali kan "shiga cikin kasuwanni masu tasowa + karuwar kasuwar a kasuwannin da suka girma" (kamar PFA a Japan da TAVR a Turai), inda ta cimma fa'idodi masu dacewa a yankuna daban-daban. Medtronic ta ƙaddamar da sashin binciken narkewar abinci mai taimakon AI.
Dangane da ƙasar Sin, a ɓangaren "Jinjiyoyin Jijiyoyi" kaɗai, takardar ta ambaci cewa "a hankali za a shawo kan tasirin tushen sayayya bisa ga yawan kayayyaki (VBP) da kuma dawo da kayayyaki daga China."
Kayayyakin zamani sun fara shiga kasuwar Amurka, tare da raguwar ci gaba a Turai da kuma karuwar da ke tasowa a kasuwannin Asiya. Kamfanoni da dama na duniya sun yi kama da suna da ra'ayin Allah; bayan maye gurbin kayayyaki a Amurka, wannan tsari yana maimaita kansa a Turai da Asiya. Ci gaban ya samo asali ne daga kirkire-kirkire ko samun sabbin abubuwa, amma yana shafar zagayowar sigar, matsalolin kirkire-kirkire, da tasirin robotics (kudaden shiga na Intuitive Surgical a duniya sun karu da kashi 23% a kwata na uku, kuma yawan tiyata ya karu da kashi 19%). Da alama ci gaban endoscopes bai yi ƙarfi ba.
Mu, Jiangxi Zhuoruihua Medical Instrument Co., Ltd., kamfani ne da ke kera kayayyaki a China wanda ya ƙware a fannin amfani da endoscopic, gami da layin GI kamar suƙarfin biops, hemoclip,tarkon polyp, allurar sclerotherapy, feshi catheter, gogewar cytology, waya mai jagora, Kwandon ɗaukar dutse, cathete na magudanar ruwa ta hanci da sauransuwanda ake amfani da shi sosai a cikinEMR, ESD, ERCPDa kuma Layin Urology, kamarrufin shiga ureteralda kuma rufin shiga urinary tare da tsotsa,0
Kayayyakinmu an ba su takardar shaidar CE, kuma masana'antunmu an ba su takardar shaidar ISO. An fitar da kayayyakinmu zuwa Turai, Arewacin Amurka, Gabas ta Tsakiya da wani ɓangare na Asiya, kuma suna ba wa abokin ciniki yabo da yabo sosai!
ZRHmed、Na'urar ɗaukar hoto ta biopsy:、Hemoclip、tarkon polyp、allurar sclerotherapy、Fesa catheter、gogewar cytology、Jagorar waya、Kwandon ɗaukar dutse、catheter na magudanar ruwa ta hanci、EMR、ESD、ERCP、UAS tare da tsotsa、Kurmin Shiga Mahaifa、Kwandon Maida Dutse Mai Fitsari、Jagorar Ilimin Urology
Lokacin Saƙo: Disamba-23-2025